Clinical Trials Sponsored by C3i Center Inc.

Total 4926 results

Masonic Cancer Center, University of Minnesota
Millennium Pharmaceuticals, Inc.

Terminated

Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders

Lymphoproliferative Disorder

United States
M.D. Anderson Cancer Center
Bayer; Celgene; Onyx Therapeutics, Inc.

Completed

Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome

Leukemia

United States
M.D. Anderson Cancer Center
Schering-Plough; Enzon Pharmaceuticals, Inc.

Terminated

DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis

Neoplastic Meningitis

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Astellas Pharma Inc; Medivation, Inc.

Active, not recruiting

Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy

Adenocarcinoma of the Prostate

United States
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Northwestern University; Dana-Farber Cancer Institute and other collaborators

Completed

Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer

Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Conquer Cancer Foundation

Recruiting

Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians

Metastatic Breast Cancer | End of Life

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Puma Biotechnology, Inc.

Recruiting

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Invasive Breast Lobular Carcinoma | Anatomic Stage I Breast Cancer | Anatomic Stage II Breast Cancer | Anatomic Stage III Breast Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Spectrum Pharmaceuticals, Inc

Active, not recruiting

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

EGFR Exon 20 Mutation | ERBB2 Gene Mutation | Recurrent Lung Non-Small Cell Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.; Stand Up To Cancer

Active, not recruiting

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Metastatic Prostate Cancer

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI); Mitaka USA, Inc.

Completed

Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer

Stage I Breast Cancer | Stage II Breast Cancer

United States
Northwestern University
American Cancer Society, Inc.; Robert H. Lurie Cancer Center

Completed

Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology (REDEFINEAYAO)

Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Ortho Biotech, Inc.

Completed

Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Karyopharm Therapeutics Inc

Completed

Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

Acute Myeloid Leukemia | Leukemia

United States
Nohla Therapeutics, Inc.
National Cancer Institute (NCI); Fred Hutchinson Cancer Center

Terminated

Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Leukemia of Ambiguous Lineage

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Completed

Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone

Prostate Cancer

United States
NSABP Foundation Inc
National Cancer Institute (NCI); Northern California Cancer Center

Completed

Fluorouracil and Leucovorin and/or Levamisole After Surgery In Treating Patients With Dukes' B Or Dukes' C Colon Cancer

Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Guardant Health, Inc.

Recruiting

Blood Test (Guardant Shield™) for Screening of Colorectal Cancer in Underserved Patients

Colorectal Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Stryker Instruments; pHLIP Inc.

Recruiting

A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery

Breast Cancer

United States
M.D. Anderson Cancer Center
Astellas Scientific & Medical Affairs, Inc.

Active, not recruiting

Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking

Ischemia

United States
Memorial Sloan Kettering Cancer Center
UE LifeSciences Inc.; Earlier.org

Active, not recruiting

Study of iBreast, a Handheld Device to Detect Breast Abnormalities During Screening Visits for Breast Cancer

Breast Screening

United States
Jennifer Choe
Arcus Biosciences, Inc.

Withdrawn

A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers (PANTHEoN)

Head and Neck Cancer | Squamous Cell Carcinoma of Head and Neck | Oropharynx Cancer | Oral Cavity Cancer | Oropharynx Squamous Cell Carcinoma | Pharynx Cancer | Larynx Cancer | Hypopharynx Cancer | Oral Cavity Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma

United States
Ohio State University Comprehensive Cancer Center
Embr Labs, Inc.

Active, not recruiting

EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer

Hot Flashes | Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ

United States
Memorial Sloan Kettering Cancer Center
Columbia University; Genentech, Inc.

Completed

Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma

Non-Hodgkin's Lymphoma

United States
University of Kansas Medical Center
American Cancer Society, Inc.

Terminated

Neuroimaging Studies of Practice and Smoking (COPE)

Smoking Cessation

United States
M.D. Anderson Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Myeloma

United States
Northwestern University
Seagen Inc.; Robert H. Lurie Cancer Center

Unknown

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | Stage II Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma

United States
Boston Medical Center
Boston University; American Cancer Society, Inc.

Completed

DOSE HPV: Development of Systems and Education to Improve HPV Vaccination Rates

Behavior
M.D. Anderson Cancer Center
Medivation, Inc.; Janssen Services, LLC

Completed

Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide

Prostate Cancer

United States
Ohio State University Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade... and other conditions

United States
Ohio State University Comprehensive Cancer Center
Astex Pharmaceuticals, Inc.

Completed

Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia

B-Chronic Lymphocytic Leukemia

United States
Fox Chase Cancer Center
National Comprehensive Cancer Network; Puma Biotechnology, Inc.

Recruiting

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Gastric Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Astex Pharmaceuticals, Inc.

Recruiting

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive | BCR-ABL1 Positive Chronic Myelogenous Leukemia | BCR-ABL1 Positive

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Trevarx Biomedical, Inc

Suspended

A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer

Breast Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.

Active, not recruiting

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Malignant Solid Neoplasm | Soft Tissue Sarcoma | Recurrent Ovarian Carcinoma | Triple Negative Breast Cancer | Recurrent Osteosarcoma | Refractory Osteosarcoma | Bone Sarcoma | Giant Cell Tumor of Bone | Ovarian Carcinosarcoma | Platinum-Resistant Ovarian Carcinoma | Dedifferentiated Chondrosarcoma | Malignancy... and other conditions

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Calithera Biosciences, Inc

Active, not recruiting

Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer

Metastatic Colorectal Cancer | Colorectal Cancer | RAS Wild Type Colorectal Cancer | Refractory Colorectal Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Completed

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma

United States
Nohla Therapeutics, Inc.
National Cancer Institute (NCI); Fred Hutchinson Cancer Center

Completed

Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute... and other conditions

United States
Case Comprehensive Cancer Center
The Cleveland Clinic; Biofrontera, Inc.

Recruiting

Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses

Actinic Keratosis

United States
Memorial Sloan Kettering Cancer Center
Astellas Pharma US, Inc.

Recruiting

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

Urothelial Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Astellas Pharma US, Inc.

Recruiting

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

United States
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.; Syndax Pharmaceuticals

Recruiting

A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

Acute Myeloid Leukemia

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca; Guardant Health, Inc.

Recruiting

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Metastatic Non-small Cell Lung Cancer

United States
M.D. Anderson Cancer Center
Apexigen America, Inc.; Pyxis Oncology

Active, not recruiting

APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

Melanoma

United States
University of Kansas Medical Center
American Cancer Society, Inc.

Active, not recruiting

Measuring Taste Perception During Chemotherapy for Muscle Invasive Bladder Cancer

Bladder Cancer

United States
Milton S. Hershey Medical Center
American Cancer Society, Inc.

Completed

End-of-Life Health Care Decisions by Patients With Advanced Cancer

Neoplasms
Memorial Sloan Kettering Cancer Center
AstraZeneca; Marker Therapeutics, Inc.

Completed

TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer

Ovarian Cancer

United States
Memorial Sloan Kettering Cancer Center
Astellas Pharma US, Inc.

Completed

Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Masonic Cancer Center, University of Minnesota
Millennium Pharmaceuticals, Inc.

Terminated

Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

United States
University of Michigan Rogel Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma

Neuroblastoma

United States
M.D. Anderson Cancer Center
Novartis Pharmaceuticals; BTG International Inc.

Withdrawn

Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease

Liver Cancer

Clinical Trials Sponsored by C3i Center Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations